Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‑18a‑3p/Gsdmd pathway

  • Authors:
    • Lin Yang
    • Chun-Feng Cheng
    • Zhi-Fang Li
    • Xiao-Jing Huang
    • Shao-Qing Cai
    • Shan-Yu Ye
    • Li-Jun Zhao
    • Yi Xiong
    • Dong-Feng Chen
    • He-Lu Liu
    • Zhen-Xing Ren
    • Hong-Cheng Fang
  • View Affiliations

  • Published online on: April 24, 2023     https://doi.org/10.3892/ijmm.2023.5252
  • Article Number: 49
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Diabetic cardiomyopathy (DCM) is a cardiovascular disease which has been reported as a major cause of mortality worldwide for several years. Berberine (BBR) is a natural compound extracted from a Chinese herb, with a clinically reported anti‑DCM effect; however, its molecular mechanisms have not yet been fully elucidated. The present study indicated that BBR markedly alleviated DCM by inhibiting IL‑1β secretion and the expression of gasdermin D (Gsdmd) at the post‑transcriptional level. Considering the importance of microRNAs (miRNAs/miRs) in the regulation of the post‑transcriptional process of specific genes, the ability of BBR to upregulate the expression levels of miR‑18a‑3p by activating its promoter (‑1,000/‑500) was examined. Notably, miR‑18a‑3p targeted Gsdmd and abated pyroptosis in high glucose‑treated H9C2 cells. Moreover, miR‑18a‑3p overexpression inhibited Gsdmd expression and improved biomarkers of cardiac function in a rat model of DCM. On the whole, the findings of the present study indicate that BBR alleviates DCM by inhibiting miR‑18a‑3p‑mediated Gsdmd activation; thus, BBR may be considered a potential therapeutic agent for the treatment of DCM.
View References

Related Articles

Journal Cover

June-2023
Volume 51 Issue 6

Print ISSN: 1107-3756
Online ISSN:1791-244X

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yang L, Cheng C, Li Z, Huang X, Cai S, Ye S, Zhao L, Xiong Y, Chen D, Liu H, Liu H, et al: Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‑18a‑3p/Gsdmd pathway. Int J Mol Med 51: 49, 2023
APA
Yang, L., Cheng, C., Li, Z., Huang, X., Cai, S., Ye, S. ... Fang, H. (2023). Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‑18a‑3p/Gsdmd pathway. International Journal of Molecular Medicine, 51, 49. https://doi.org/10.3892/ijmm.2023.5252
MLA
Yang, L., Cheng, C., Li, Z., Huang, X., Cai, S., Ye, S., Zhao, L., Xiong, Y., Chen, D., Liu, H., Ren, Z., Fang, H."Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‑18a‑3p/Gsdmd pathway". International Journal of Molecular Medicine 51.6 (2023): 49.
Chicago
Yang, L., Cheng, C., Li, Z., Huang, X., Cai, S., Ye, S., Zhao, L., Xiong, Y., Chen, D., Liu, H., Ren, Z., Fang, H."Berberine blocks inflammasome activation and alleviates diabetic cardiomyopathy via the miR‑18a‑3p/Gsdmd pathway". International Journal of Molecular Medicine 51, no. 6 (2023): 49. https://doi.org/10.3892/ijmm.2023.5252